A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

November 4, 2023

Study Completion Date

November 4, 2023

Conditions

Healthy

Interventions

DRUG

[14C]-LY3556050

Administered orally

Trial Locations (1)

LabCorp CRU, Inc., Madison

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06052462 - A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants | Biotech Hunter | Biotech Hunter